Eastern Mediterranean Health Journal |
Back to Health Journal page |
Health Journal back issues |
Home
|
Seroepidemiological
survey of rubella immunity among three populations in Shiraz, Islamic
Republic of Iran
M. Doroudchi,1 A.Samsami. Dehaghani,2 K. Emad 3 and A.A. Ghaderi 1 1Department of Immunology; 2 Department of Obstetrics and Gynaecology; 3Department of Paediatrics, Shiraz University of Medical Sciences, Shiraz, Islamic Republic of Iran. |
| Volume 7, Nos 1/2, January-Match 2001, Page 128-138 |
مسح
مصلي وبائي
لمناعة
الحصبة
الألمانية
بين ثلاثة
مجتمعات في
شيراز
بجمهورية
إيران
الإسلامية
خلاصـة:
استخدمنا
مقايسة
الإليزا
اللامباشرة
فـي فحـص 1193
عينـة مصـل
بحثـاً عـن
أضـداد
الحصبـة
الألمانيـة
من صنف
(
الأيج جIgG
،
والأيج م IgM،)
وذلك في مسح مصلي وبائي أجريناه على ثلاث عينات سكانية مختلفة بحسب السن والجنس في شيراز. وشملت الدراسة 203 من الأطفال الذين تبلغ أعمارهم 2-7 سنوات، و255 من ثنائيات الأمهات والوِلْدان (عينات من دم الحبل السري)، و400 فتاة وسيدة تبلغ أعمارهن 14-70 سنة. وتبيَّن أن إيجابية المصل بين النساء اللواتي تتراوح أعمارهن بين 14 و70 سنة من العمر كانت بنسبة 96.2%. ولم توجد في عينات دم الحبل السري وعددها 255 أي عينة إيجابية للأيج م. وبلغت إيجابية الأمصال بين الأطفال المئتين وثلاثة نسبة 97.0% (أعلى كثيراً مما تضمَّنته التقارير من قبل). وربما كان سبب ذلك أوبئة الحصبة الألمانية التي يتواتر حدوثها كل ست إلى عشر سنوات. وتناقش المقالة تأثير تطبيق التطعيم ضد الحصبة الألمانية. ABSTRACT
We
used indirect ELISA assay to test 1193 sera for rubella IgG and IgM
antibodies in a seroepidemiological survey of three age- and
gender-differentiated sample populations in Shiraz: 203 children aged
2–7 years, 255 paired mothers and neonates (cord blood) and 480
women aged 14–70 years. Seropositivity among women aged 14–70
years was 96.2%. No IgM positive case was found among the 255 tested
cord blood samples. Seropositivity among the 203 children was 97.0%
(much higher than previously reported). This may be due to rubella
epidemics, which tend to occur every 6–10 years. The impact of
introducing rubella vaccination is discussed. Enquête
séro-épidémiologique sur l'immunité contre la rubéole dans trois
populations à Chiraz (République islamique d'Iran) RESUME
Nous avons utilisé la méthode immuno-enzymatique indirecte pour
tester 1193 sérums à la recherche d'anticorps IgG et d'IgM antirubéoleux
dans une enquête séro-épidémiologique comprenant trois populations
de l'échantillon différenciées par l'âge et le genre à Chiraz :
deux cent trois (203) enfants de 2 à 7 ans, 255 mères et nouveau-nés
appariés (sang du cordon) et 480 femmes âgées de 14 à 70 ans. La séropositivité
parmi les femmes âgées de 14 à 70 ans s'élevait à 96,2 %. Aucun
cas IgM positif n'a été trouvé dans les 255 échantillons
de sang de cordon
testés. La séropositivité
parmi les 203
enfants s'élevait à
97,0 % (bien supérieure à ce qui avait été signalé précédemment).
Ceci peut être dû aux épidémies de rubéole qui ont tendance à
survenir tous les 6-10 ans. L'impact de l'introduction de la
vaccination contre la rubéole fait l'objet d'un examen. Introduction Rubella
is an exanthem disease of childhood, presenting with rash, fever and
lymphadenopathy. It is a disease with a high risk of damage to the
fetus. Since 1970, comprehensive vaccination against rubella has been
undertaken in industrialized countries [1]. In the past few
years, some developing countries have begun the vaccination programme
against rubella [2]. Although rubella is endemic in the Islamic Republic of Iran,
there is a lack of adequate information about the immune status of
populations to the disease in different parts of the country. Rubella
vaccination is currently not considered a health priority in the
country. However, the high risk of damage to fetal organs and
congenital malformations after intrauterine infection, coupled with
the endemicity of the disease in the Islamic Republic of Iran, would
suggest the necessity of vaccinating those at risk in the population.
Selection of an appropriate, efficacious policy of vaccination is,
therefore, needed. Different vaccination strategies are used in
different parts of the world [3–5], including: universal
vaccination of children and susceptible adults; vaccination of
15–24-month-old children, as well as children entering or ending
school; and vaccination of 12–13-year-old girls, and women in the
post-partum period. However, in populations with high levels of
natural immunity in women of childbearing age, premarital testing and
vaccination of seronegative females is recommended [6]. Considerable geographic variations in the seropositivity rate
for rubella because of differences in temperature have been reported
by other investigators [7]. However, adequate information about
immunity to the disease in different parts of the Islamic Republic of
Iran is missing. The results of the few investigations undertaken
reveal a high seropositivity rate, ranging from 74.8% among women of
childbearing age in Ahwaz and Dezful [8] to 97.5% among
children by age 15 years in Teheran [9]. However, cases of
congenital rubella syndrome have been reported in Ahwaz and Dezful
where high temperatures and a low seropositivity rate coexist. In order to design an efficient and economical vaccination
policy, it is necessary to have adequate information about the immune
status in different geographical parts of the country, with the
different climates in different time intervals. Most of the
information about rubella epidemiology in the Islamic Republic of Iran
is limited to a few geographical regions in discontinuous time
intervals. A major reason for this lack of information is because of
the high cost of the commercial rubella kits available for such
studies — the availability of homemade assays would clearly be more
cost-effective. To achieve this, an indirect enzyme-linked
immunosorbent assay (ELISA) was de-signed and standardized according
to World Health Organization standard serum to perform a quantitative
test. Since 1991, when a rubella outbreak was reported in Shiraz [10],
there has been no official report of seroprevalence of rubella
immunoglobulins in the city. Therfore a seroepi-demiological survey
was performed on 1193 sera from three different populations according
to age and sex. Methods The
study population consisted of three age groups. There were 203 blood
samples collected from children (ages 2–7 years) with no major
health problem referred to Shahid Rezaiee Polyclinic, Shiraz; 255
paired maternal and cord blood samples collected from pregnant women
(ages 14–40 years); and 480 blood samples collected from women (ages
15–70 years) attending the Zeinabie Gynaecologic Clinic for routine
examination. Sera were separated from blood samples on the same day of
sampling, aliquoted in 0.5 mL volumes, and stored at –20 °C until
use. Demographic data, including age, sex, number of children,
previous abortions, abnormalities in the family and address were
collected at the time of sampling. Takahashi
strain of rubella virus, which is used for optional vaccination in the
Islamic Republic of Iran, was cultured in Vero cell line. Monolayers
of Vero cell line were grown in RPMI-1640 containing 10% fetal bovine
serum at 37 °C in a 5% carbon dioxide-containing atmosphere. At the
time of confluency (2–3-day-old cultures), cul-tures were washed
with Hanks balanced salt solution, and rubella seed virus 103
TCID50 in 2 mL was added. After 1 hour, adsorption at room temperature
with per-iodic rolling, followed by 3 hours at 37 °C, maintenance
medium containing 3% fetal bovine serum was added to each mono-layer.
Maintenance medium was replaced, 48 hours after infection, with
RPMI-1640 medium without serum. To achieve high titre stocks of virus
and to restrict defec-tive interfering particles during serial
un-diluted passage, rubella virus was alternatively passaged on Vero
and BHK-21 cell lines [11]. Detergent-solubilized
whole virus preparations were prepared according to the method
described by Mitchell et al. [12,13]. In brief, Takahashi
strain of virus was grown on monolayers of Vero cells and harvested
from culture fluids 72, 96 and 120 hours after infection. Culture
supernatants were pooled and clarified by centrifugation at 1000 × g
for 20 minutes at 4 °C. The clarified culture supernatant was
concentrated by polyethylene glycol 6000 precipitation by adding 2.2%
(w/v) sodium chloride followed by 6% (w/v) polyethylene glycol 6000.
After overnight incubation at 4 °C with continual stirring, the fluid
was pelleted by centrifugation at 1000 × g for 1 hour at 4 °C. The
viral pellet was resuspended in proper volume of phosphate-buffered
saline containing 0.5% Triton X-100. Using mock-infected culture supernatant of Vero cells, a control antigen was prepared using the same procedure as rubella antigen and used in an indirect ELISA assay, including eight positive sera with different but known concentrations of anti-rubella IgG. Only two sera revealed an absorbance of more than 0.6, which was equal to 20 IU/mL in the assay. However, the reactivity of these sera with rubella antigen was much greater (Table 1). Table 1 Comparison of the absorbance of 8 tested sera with control and rubella antigens prepared from mock infected and rubella virus-infected culture supernatant fluid
Different
concentrations of Triton X-100-solubilized rubella antigen were
titrated against negative and positive control sera of a commercial
kit (Alfa Biotech, Italy) containing 0, 6.25, 12.5, 25, 50 and 100
IU/mL anti-rubella IgG to find the best concentration for antigen
coating. Rubella antigen was diluted in carbonate–bicarbonate buffer
(pH = 9.6) and coated onto the ELISA plate in proper concen-tration.
Unbound antigen was washed three times with phosphate buffered saline
con-taining 0.05% Tween 20, and plates were blocked with phosphate
buffered saline containing 1% gelatine for 1 hour at 37 °C. After the
next three washes, patient sera (diluted 1:100) were added to wells
and incubated at 37 °C for 1 hour. Each plate contained a 6-point
dilution series of a pooled serum, which was standardized against WHO
RV-IgG reference serum (NIBSC, United Kingdom). A blank well
containing phosphate buffered saline Tween 20 instead of serum was
also included in each plate. Specific IgG was detected using a
horseradish peroxidase-conjugated goat anti-human IgG (Calbio-chem,
United States of America). Optimally diluted, labelled anti-IgG was
added onto ELISA plates and incubated for 45 minutes at 37 °C. After
the final three washes with phosphate buffered saline Tween 20,
en-zyme substrate, orthophenylene diamine dihydrochloride (DAKO,
Denmark) and hydrogen peroxide in citrate buffer (pH = 5.5) were added
in 100 µL volumes. Colour development was allowed to continue for 10
minutes and then
stopped by
adding 50 µL of 12.5% sulfuric acid
solution. Absorbance was measured at 490 nm using an ELISA
spectrophotometer (Titertecplus-MS2 reader, Finland). Concentrations
of rubella virus-specific IgG (IU/mL) were determined from standard
curves plotted for each plate by the formula: lnY
= ao + a1
lnX where
Y is absorbance value as dependent variable, X is the
concentration of anti-rubella IgG in sera, ao
is the Y intercept and a1
is the slope of the fitted line. Since levels of 19.0 ± 3.7 IU/mL in the in-house whole-virus
ELISA were shown to be equal to 15.3 ± 2.4 IU/mL in the DiaMedix
commercial assay [12], the level of 20 IU/mL was considered as
the baseline for detection of negative cases. To detect IgM
anti-rubella antibody, coating, blo-cking, serum dilution and
incubation times and temperatures were performed as for the
IgG-rubella assay. To avoid the effect of potentially present
rheumatoid factor and to remove the unwanted competition of IgG
antibodies with IgM antibodies, total serum IgG was absorbed by adding
goat anti-human IgG in proper dilution at the time of serum addition.
Positive, negative and cut-off sera of a commercial kit (Alfa Biotech,
Italy) were included in the assay. Absorbance was measured at 490 nm
and positive and negative results were deter-mined according to the
cut-off value. The
student t-test for unpaired and paired samples was used to
compare the mean concentration of anti-rubella IgG between the study
groups. The chi-squared test was used to evaluate the effect of
different factors on seropositivity rate. The Levene test was used to
analyse the homogeneity of variances of anti-rubella IgG concentration
between groups. Statistical analyses were performed using SPSS,
version 6.0. Results In total, 735 serum samples of women aged 14–70 years and 203 serum samples from children aged 2–7 years were col-lected from December 8, 1998 to February 20, 1999. Of 735 female subjects, the sera of 255 pregnant mothers were also grouped with the paired cord blood sam-ples collected at the time of delivery. Of 643 samples with known address, 262 (40.7%) were collected from women who lived in areas surrounding Shiraz city (rural) and 381 (59.3%) from women who lived in Shiraz city itself (urban). Of 666 serum samples for which the number of children in the family was known, 513 (77.0%) belonged to women with fewer than 3 children, 99 (14.9%) belonged to women with 3–5 children and 54 (8.1%) belonged to women who had 6 or more children. Among women of childbearing age, 606 had no history of abortion and 129 had at least one case of abortion (86 had had one, 30 had had two and 13 had had more than two). Of the 735 women, 46 reported abnormality among their children or a close relative.
The
rate of seropositivity among women was found to be 96.2% (707 out of
735). The average age ± standard deviation of the test group was 26
± 8 years and the mean IgG
concentration was 111.13 ± 60.79 Of the 262 rural and 381 urban women, 9 (3.4%) and 11 (2.9%)
respectively were negative.
The difference was not statistically significant. However the mean
concentration of rubella-specific IgG in rural cases (mean ± standard
deviation = 103.64 ± 61.58 IU/mL) was significantly lower than in
urban cases (117.59 ± 59.59 IU/mL) (Student t-test, P
< 0.05). A higher percentage of seronegativity was found in women with
fewer than 3 children compared to women with 3 or more children (3.9%
versus 1.3%), although this was not significant. The mean
concentration of rubella-specific IgG in the former group was
significantly lower than in the latter (108.44 ± 59.04 IU/mL versus
119.88 ± 63.20 IU/ml) (P < 0.05). Table 2 Anti-rubella IgG concentration in 643 women by age, Shiraz, Islamic Republic of Iran
s = standard deviation. The
mean concentration of anti-rubella IgG in mothers’ sera (109.98 ±
54.18 IU/mL) was significantly higher than the mean concentration of
anti-rubella IgG in cord blood samples (91.39 ± 54.03 IU/mL) (Student
t-test for paired samples, P < 0.001). Of
255 mothers, 2 had < 20 IU/mL anti-rubella IgG and were thus
considered negative. However, the number of negative cases was higher
(10 out of 255) among neonates. Of the seronegative neonates, two were
born of mothers who were seronegative, and were in the youngest age
group (i.e. < 20 years old). The eight others were born of mothers
with anti-rubella IgG concen-tration of < 50 IU/mL. A comparison of
the representative data for mothers and neo-nates is shown in Table 3. Table 3 Comparison of anti-rubella IgG in mothers’ sera and the corresponding cord sera (n = 255)
The
mean age ± standard deviation was 4.5 ± 1 years. The seropositivity
rate in the children was 97% and the mean concen-tration of specific
IgG was 131.21 ± 71.24 IU/mL. Of 203 serum samples in this age group,
6 (3.0%) had an anti-rubella IgG concentration of < 20 IU/mL
(Figure 2). Of these, 5 of 102 (4.9%) were males and 1 of 101 (1.0%)
was female. However, the observed difference was not significant. The
mean concentration of anti-rubella IgG for males was 136.06 ± 73.95
IU/mL, compared to 127.61 ± 67.72 IU/mL for females. The
mean concentration of anti-rubella IgG in women’s sera was
significantly lower than in children’s sera (111.13 IU/mL compared
to 131.21 IU/mL). In addition, the distribution of IgG concentrations
around the mean was significantly different between these groups
(Levene test of homogeneity, P < 0.05). In this regard, the
variation in anti-rubella IgG concentration in children was
significantly higher than in women. To
assess possible rubella infection of the neonates, 255 cord blood
samples were tested in an IgM-ELISA assay. No IgM-positive case was
detected. Discussion The
observed 96.2% seropositivity rate among women of childbearing age is
comparable to the reported prevalences of 93% [14] and 94.9% [15]
of the same age group in the Islamic Republic of Iran. Since the study
population was from a low socioeconomic population, the high
seropositivity rate is not unexpected. Saidi et al. reported the
seropositivity rate in a low socioeconomic group to be as high as 99%,
compared to 92% in the high socioeconomic group in their study [14].
In a study between 1993 and 1995, Modarres et al. reported
seropositivity to be 96.5% in a low socioeconomic group compared to
93% in the high socioeconomic group [15]. The rate of
seropositivity in our study is also comparable to Saudi Arabia [16,17],
Kuwait [18], Nigeria [19], Bahrain [20], Gambia [21],
Turkey [22] and India [23]. However, it is much higher
than the reported prevalence in Taiwan [24,25], Angola and
Ghana [26]. The frequency of seropositivity in urban participants was
slightly higher than in rural participants (97.1% versus 96.6%), but
this was not statistically significant. This might be due to the fact
that the rural participants were from villages very close to Shiraz,
and the same factors involved in the spread of the virus in the city
would also have influenced the epidemiology of the disease in these
areas. In addition, the mean anti-rubella IgG concentration was
significantly lower in rural participants compared to urban
participants. Similarly, Saidi reported a lower
haemagglutination-inhibition titre in rural cases compared to urban
cases (1:138 versus 1:165) [14]. In previous studies, family density had been reported to
influence the level of rubella antibody [5]. In the present
study, the mean IgG concentration in women with fewer than 3 children
was lower than those with 3 or more children. The mean concentration of anti-rubella IgG in cord sera was
significantly lower (P < 0.001) than that of mothers’
sera. Also, the frequency of seronegative cases was found to be
significantly higher in cord blood samples. There were eight low
positive and two seronegative mothers who gave birth to neonates who
were seronegative. This lack of transmission of specific antibodies
has been previously reported for measles and tetanus [27]. In a
study of transplacental transfer of toxoplasmosis antibodies among
European and African cord–mother pairs, a lack of transfer was found
among African, but not European pairs [28]. Shortridge and
Osmund [29] reported the incidence of maternally acquired
rubella antibody to be 84% for the Chinese population and 90% for
Caucasians in Hong Kong. They also reported a decrease in this
incidence to 54% in Chinese, but not Caucasians, by 2 months. In this
regard, the higher concentrations of rubella and measles antibodies in
North American or European mother–neonate pairs have been reported
in cord blood samples [30]. Ethnic differences and differences
in level of specific antibody have been considered possible
explanations for these inconsistencies [27,31]. In African
mothers who had high levels of antibody and who lived in countries
with a high endemicity rate of infectious diseases, higher levels of
tetanus antibody revealed a positive correlation with lack of antibody
transfer to the fetus [28]. However, in our study we found the
opposite to be the case for the transfer of rubella antibody. The seropositivity rate among children aged 2–7 years was
found to be 97%, much higher than previous reports. Saidi reported a
rate of 58% for the same age group [14]. In 1970, Naficy et al.
reported a rate of 46.5% [9] and in 1996, Modarres et al.
reported a rate of 50% for the age group of 1–10 years [15].
The rate of seropositivity among children < 10 years of age in
Shiraz had been reported as 46.5% during 1986–90 [10].
However, the authors reported evidence of an outbreak in 1991 in
Shiraz, through which the rate of sero-positivity increased to 94.5%.
There is no official report on the duration of rubella outbreaks in
the Islamic Republic of Iran. However, it can be seen from reports
from the United States of America and United Kingdom in the
pre-vaccination era, that rubella outbreaks seem to appear in
6–9-year cycles. Since the present study was undertaken 8 years
after the above-mentioned report, it is likely that we faced another
outbreak in Shiraz during the sampling period. It is noteworthy that
greater variation in the concentration of anti-rubella IgG was found
among children than among the women’s group. This var-iation might
be due to an active immu-nological response among children who faced
rubella virus for the first time. In the few reports of the seroepidemiology of rubella from
different parts of the country, prevalence rates of 70% to more than
95% are reported among women of childbearing age [8,9,10,14,15].
It seems that in the highly populated urban areas with temperate
climates, most of the girls develop anti-rubella IgG by the age of 15
years [9,14,15]. In our study, the seropositivity rate (96.2%)
among women in an urban setting with a temperate climate was much
higher than the rate reported in Ahwaz and Dezfal (74.8%), a hot area
of the country [8]. However, our results are comparable with
rates reported from other areas of the country with a temperate
climate [15]. To date, rubella vaccination has not been considered a health
priority in the Islamic Republic of Iran. However, due to highly
variable climate in different parts of the country, deciding on a
“yes” or “no” vaccination policy might be reconsidered. It
should be noted that most of the studies from which information about
Iranian seropositivity rates are drawn are from urban areas with
temperate climate. However, in some parts of the country, lifestyles
are completely different from urban and even rural life. Some
migrating tribes are not settled in a defined place. No data exist
about rubella immunity in such tribes. Previous investigations have shown that the age incidence of
rubella infection in the Islamic Republic of Iran is low [14,15].
The introduction of vaccination in other parts of the world has been
accompanied by a shift in the age incidence of rubella infection to
older age groups [1]. The age of women at marriage in many
parts of the Islamic Republic of Iran, especially in rural areas, is
low (12–17 years of age). Unless vaccination of all at-risk
populations is undertaken, any immunization programme would change the
pattern of rubella epidemiology such that the risk of infection for
older groups may increase, and the risk of reinfection with wild
strains after vaccination may arise. Acknowledgement We
would like to thank Mr Mehdi Muhammadi of the Biostatistics Department
of Shiraz University of Medical Sciences for his generous cooperation
in performing the statistical analyses. References 1.
Rubella and congenital rubella - United States, 1984–1986. Morbidity
and mortality weekly report, 1987, 36:664–76. 2.
World Health Organization. Expanded programme on immunization
(EPI). Weekly epidemiological record, 1996, 23:173–80. 3.
Gale JL et al. The epidemiology of rubella in Taiwan. II.
1968–1969 epidemic. International journal of epidemiology,
1972, 1:253–60. 4.
Jackson BM et al. An epidemiologic investigation of a rubella
outbreak among the Amish of north-eastern Ohio. Public health
reports, 1993, 108:436–9. 5.
Preblud SR et al. Rubella vaccination in the United States: a
ten-year review. Epidemiologic reviews, 1980, 2:171–94. 6.
Hathout H et al. Seroepidemiology of rubella in Kuwait: an
alternative vaccination policy. International journal of
epidemiology, 1978, 7:49–53. 7.
Best JM et al. New Japanese rubella vaccine: comparative
trials. British medi-cal journal, 1974, 3:221–4. 8.
Pakzad P, Ghafourian M. Rubella survey among pregnant women and
congenitally infected infants in Khouzestan
province Medical journal of Ahwaz. University of Medical
Sciences, 1996, 19:56–66. 9.
Naficy K, Saidi S. Serological survey on viral antibodies in
Iran. Tropical and geographical medicine, 1970, 22:183–8. 10.
Kabiri M, Moattari A. The rubella immunosurveillance of Iranian
females: an indication of the emergence of rubella outbreak in Shiraz,
Iran. Iranian journal of medical sciences, 1993, 18:134–7. 11.
Terry GM et al. Rubella virus RNA: effect of high multiplicity
passage. Archives of virology, 1985, 86:29–36. 12.
Mitchell LA et al. Characterization of rubella virus-specific
antibody responses by using a new synthetic peptide-based
enzyme-linked immunosorbent assay. Journal of clinical microbiology,
1992, 30:1841–7. 13.
Zhang DX et al. Detection of rubella virus-specific
immunoglobulin G (IgG), IgM, and IgA antibodies by immunoblot assays. Journal
of clinical microbiology, 1992, 30:824–30. 14.
Saidi S. Epidemiological survey of rubella immunity in Iran. Bulletin
of the World Health Organization, 1972, 46:563–5. 15.
Modarres S, Modarres S, Oskoii NN. The immunity of children and
adult females to rubella virus infection in Tehran. Iran-ian
journal of medical sciences, 1996, 21:69–73. 16.
Abdullah MA et al. Seroepidemiology of rubella in Saudi Arabia:
an adapted vaccination policy. Journal of epidemiology and
community health, 1984, 38:236–9. 17.
Hossain A. Seroepidemiology of rubella in Saudi Arabia. Journal
of tropical pediatrics, 1989, 35:169–70. 18.
Al-Nakib W et al. Seroepidemiology of viral and toxoplasmal
infections during pregnancy among Arab women of childbearing age in
Kuwait. International journal of epidemiology, 1983,
12:220–3. 19.
Gomwalk NE, Ahmad AA. Prevalence of rubella antibodies on the
African continent. Review of infectious diseases, 1989,
11:116–21. 20.
Dutta SR et al. Seroepidemiology of rubella in Bahrain. International
journal of epidemiology, 1985, 14:618–23. 21.
Mingle JAA. Frequency of rubella antibodies in the population
of some tropical African countries. Review of infectious diseases,
1985, 7(S1):68–71. 22. Aksit S
et al. Rubella seroprevalence in an unvaccinated population in Izmir:
recommendations for rubella vaccination in Turkey. Pediatric
infectious disease journal, 1999 18:577–80. 23. Bhaskaram
P et al. Need for protection against rubella in India. Indian
journal of pediatrics, 1991, 58:811–4. 24. Lin DB,
Chen CJ. Current seroepidemiology of rubella virus infection among
female residents in Taiwan. Journal of medical virology, 1993,
41:174–8. 25. Yuan C
et al. Seroepidemiologic study of rubella in selected Chinese female. Chung
Hua I Hsueh Tsa Chih (Taipei), 1989, 43:85–8. 26. Arroyo
M et al. Natural immunity to measles, rubella and mumps among Spa-nish
children in the pre-vaccination era. International journal of
epidemiology, 1986, 15:95–100. 27. Gendrel
D et al. Placental transfer of tetanus antibodies and protection of
the newborn. Journal of tropical pediatrics, 1990, 36:279–82. 28. Richard-Lenoble
D et al. Passage transplacentaire des anticorps toxoplasmi-ques.
Difference entre la mere africaine et europeenne. [Transplacental
passage of toxoplasma antibodies. The dif-ference between African and
European mothers]. Bulletin de la Societe de Pa-thologie Exotique
et de ses filiales, 1988, 81:365–8. 29.
Shortridge KF, Osmund IF. Seroepidemiology of rubella infection
in Chinese and Caucasians in Hong Kong. Journal of hygiene,
1979, 83:397–403. 30.
Sato H et al. Transfer of measles, mumps and rubella antibodies
from mother to infant. Its effect on measles, mumps and rubella
immunization. American journal of diseases in childhood, 1979,
133: 1240–3. 31.
Skendzel LP et al. Evaluation of assays for the detection of
antibodies to rubella: a report based on data from the College of
American Pathologists Surveys of 1982. American journal of clinical
pathology, 1983, 80(S):594–8. |
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||